Mitchell D Schnall Selected Research

Breast Neoplasms (Breast Cancer)

6/2018	MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
1/2017	MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.
1/2017	No impact of breast magnetic resonance imaging on 15-year outcomes in patients with ductal carcinoma in situ or early-stage invasive breast cancer managed with breast conservation therapy.
4/2016	Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
5/2015	Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures.
10/2014	Contralateral prophylactic mastectomy in the American College of Radiology Imaging Network 6667 trial: effect of breast MR imaging assessments and patient characteristics.
1/2014	Optically measured microvascular blood flow contrast of malignant breast tumors.
5/2013	Mammographic parenchymal patterns as an imaging marker of endogenous hormonal exposure: a preliminary study in a high-risk population.
1/2013	Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy.
6/2012	Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mitchell D Schnall Research Topics

Disease

28	Neoplasms (Cancer) 12/2020 - 03/2002
14	Breast Neoplasms (Breast Cancer) 06/2018 - 03/2003
3	Glioma (Gliomas) 01/2020 - 01/2017
2	Multiple Sclerosis 01/2022 - 09/2019
2	Pathologic Complete Response 06/2018 - 04/2016
2	Carcinoma (Carcinomatosis) 01/2017 - 12/2002
2	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2017 - 01/2006
2	Fibroadenoma 07/2014 - 07/2002
2	Renal Cell Carcinoma (Grawitz Tumor) 04/2008 - 01/2007
2	Carcinogenesis 01/2007 - 12/2002
2	Prostatic Neoplasms (Prostate Cancer) 06/2004 - 01/2003
1	Stable Angina 12/2020
1	Pathologic Constriction (Stenosis) 12/2020
1	Death (Near-Death Experience) 12/2020
1	Myocardial Infarction 12/2020
1	Residual Neoplasm 04/2016
1	Lymphoma (Lymphomas) 01/2016
1	Fibrosis (Cirrhosis) 08/2015
1	Necrosis 08/2015
1	Triple Negative Breast Neoplasms 07/2014
1	Carcinoma in Situ 01/2007
1	Lymphadenopathy 04/2004
1	Margins of Excision 01/2003
1	Cysts 03/2002

Drug/Important Bio-Agent (IBA)

5	GadoliniumIBA 01/2022 - 05/2004
5	Contrast MediaIBA 01/2017 - 03/2003
5	Hemoglobins (Hemoglobin)IBA 05/2015 - 07/2002
3	Biomarkers (Surrogate Marker)IBA 12/2020 - 05/2015
2	Biological ProductsIBA 01/2020 - 05/2013
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2020 - 01/2016
2	Sweetening Agents (Sweeteners)IBA 01/2019 - 01/2017
2	Protons (Proton)IBA 01/2019 - 01/2016
2	Hormones (Hormone)IBA 04/2016 - 06/2004
2	ErbB Receptors (EGF Receptor)IBA 04/2016 - 07/2014
1	omega-Chloroacetophenone (Mace)IBA 12/2020
1	Glutamic Acid (Glutamate)FDA Link 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 01/2020
1	Glutamine (L-Glutamine)FDA Link 01/2020
1	Aminobutyrates (Aminobutyric Acid)IBA 01/2020
1	Acetates (Acetic Acid Esters)FDA Link 01/2020
1	Hydroxyl RadicalIBA 01/2019
1	maltitolIBA 01/2019
1	Sugar AlcoholsIBA 01/2019
1	SolutionsIBA 01/2017
1	trichlorosucrose (sucralose)IBA 01/2017
1	Pentetic Acid (DTPA)FDA LinkGeneric 01/2017
1	Pyruvic Acid (Pyruvate)IBA 01/2016
1	A 19IBA 08/2015
1	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 08/2015
1	Oxygen (Dioxygen)IBA 05/2015
1	Complement System Proteins (Complement)IBA 05/2015
1	Estrogen ReceptorsIBA 07/2014
1	taxaneIBA 06/2012
1	AnthracyclinesIBA 06/2012
1	N 30IBA 12/2008
1	Sorafenib (BAY 43-9006)FDA Link 04/2008
1	Angiogenesis InhibitorsIBA 04/2008
1	Pharmaceutical PreparationsIBA 01/2007
1	Tumor Biomarkers (Tumor Markers)IBA 08/2006
1	CytokinesIBA 08/2006
1	Prostate-Specific Antigen (Semenogelase)IBA 06/2004
1	P-2 (P 2)IBA 05/2004
1	AndrogensIBA 01/2003
1	Doxycycline (Periostat)FDA LinkGeneric 12/2002
1	Tetracycline (Achromycin)FDA LinkGeneric 12/2002
1	ElementsIBA 03/2002
1	Vitamin E FDA LinkGeneric 03/2002

Therapy/Procedure

7	Therapeutics 12/2020 - 01/2003
6	Neoadjuvant Therapy 06/2018 - 06/2012
3	Segmental Mastectomy (Lumpectomy) 01/2017 - 02/2004
3	Radiotherapy 01/2017 - 01/2003
2	Aftercare (After-Treatment) 12/2014 - 04/2004
2	Prophylactic Mastectomy 10/2014 - 03/2003
1	Mastectomy (Mammectomy) 01/2006
1	Prostatectomy (Retropubic Prostatectomy) 01/2003